Scil Proteins Obtains EMA Approval for Commercial Production of Reteplase

Scil Proteins Production GmbH announced today that the European Medicines Agency (EMA) has approved Scil Proteins’ Halle facilities for manufacturing of Reteplase, marketed by Actavis as Rapilysin®.